July 22, 2018

Creative Planning Purchases 9000 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

12 August 2017, 10:54 | Rodolfo Wallace

The stock is trading at $19.72 which is well above the 50 day moving average which is $16.99 and marginally over the 200 day moving average of $18.99. Chardan maintained its investment rating on the stock at buy. As of the latest earnings report the EPS was $-3.09 and is estimated to be $-3.04 for the current year with 40,729,000 shares now outstanding. To conclude comes the ratings part in which the company was evaluated with "2" Analysts of WSJ going for Buy ratings in current phase.

Several research analysts have commented on the company. Finally, Driehaus Capital Management LLC increased its stake in shares of Editas Medicine by 169.8% in the first quarter. This is well above the stock's Wednesday closing price of $17.98 each.

On the other hand Editas Medicine Cmn (NASDAQ:EDIT) has Relative Strength Index (RSI 14) of 65.92 along with Average True Range (ATR 14) of 1.17. State Street Corp boosted its stake in shares of Editas Medicine by 2.4% in the fourth quarter. Cann assumed coverage on shares of Editas Medicine in a report on Monday, July 17th. The business's revenue was down 8.8% on a year-over-year basis. (EDIT) on Wednesday reported a loss of $26.4 million in its second quarter. Research firm Zacks lifted Editas Medicine from a "hold" recommendation to a "buy" recommendation and fixed a $19.00 price target for The corporation in a note on Wed, Jul 12th. crowd sourced stock rating company Vetr lifted Editas Medicine from a "buy" recommendation to a "strong-buy" recommendation and fixed a $27.14 target price for The corporation in a note on Mon, Mar 20th.

COPYRIGHT VIOLATION WARNING: "Editas Medicine, Inc". The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million.

Taking a closer look into the volatility on shares of CRISPR Therapeutics AG (:CRSP), we notice that the stock is 13.39% off of the 20-Day Simple Moving Average. And it remains to be seen which target price EDIT can achieve without sacrificing much as the company is holding a -8.28% fall for the past twelve months. The stock now has a Market Cap of $14.76B. Bank of America Corp DE now owns 5,936 shares of the company's stock worth $133,000 after buying an additional 2,489 shares during the period. Of those insider trades, 39,000 shares of Editas Medicine, Inc. were purchased and 1,000,000 shares were sold.

Kris Jenner defends Life of Kylie after 'boring' criticism from fans
Kardashian West, 36, is also one of Jenner's style icons - unsurprisingly, she gets most of her style inspo from her famous family and friends.

Stocks plunge over North Korea tensions
Inflation has risen 1.7 percent over the past 12 months, suggesting that inflation pressures remain well under control. Gold futures for December delivery climbed 1.3 per cent to settle at $1,279.30 (U.S.) an ounce on the Comex in NY .

Eight army personnel among 15 martyred in Quetta's Pishin stop blast
The bomb went off at the busy Pishin Stop triggering a fire on several vehicles parked nearby. Fire fighting vehicles were able to douse the fire which had spread to multiple vehicles.

Presently Editas Medicine, Inc. The firm owned 9,101 shares of the company's stock after buying an additional 9,000 shares during the period. Next quarter's EPS is estimated at $-0.78 with next year's EPS anticipated to be $-3.20. Driehaus Capital Management has an ownership of 125,684 stocks of the firms shares valued $2,805,000 after scooping up an extra 79,104 shares through out the quarter. large institution funds own 67.87% of the firms stock. Hershey Trust Co. purchased a new stake in shares of Editas Medicine during the second quarter worth approximately $244,000.

On July 18, 2017 Oppenheimer initiated coverage giving it an initial rating of "Perform". Editas Medicine reported sales of $3.39 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15%. Also, Director Boris Nikolic bought 35,000 shares of the company's stock in a transaction on Friday, June 2nd. A total number of 5 analysts provided estimations over revenues. The shares were bought at an average price of $14.15 per share, for a total transaction of $56,600.00. The Director now owns $47,551,448 of the stock per the Form 4 SEC filing. If you are accessing this report on another publication, it was illegally copied and republished in violation of global trademark & copyright laws. The original version of this news story can be accessed at

Kevin Bitterman, Director disclosed the sale of 1,000,000 shares of (EDIT). Following the completion of the transaction, the insider now directly owns 4,000 shares in the company, valued at approximately $56,600.

Editas Medicine, Inc is a genome editing company. The information was declared in a document with the Security and Exchange Commission, which is available at this link. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes.

From another technical standpoint, Editas Medicine, Inc. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Other News

Trending Now

Guardiola: I'm so happy with this Man City squad
He has to be strong but, of course, his quality is flawless for the way we want to play. He has to be strong but, of course, his quality is ideal for the way we want to play.

SpaceX's Dragon Spacecraft to Launch First supercomputer to ISS Next Week
Each month, astronauts in the ISS receive new laptops as the atmosphere of space degrades the technology at an accelerated rate. He will keep watch on his brainchild, the Spaceborne Computer-on the mission very closely over the next 12 months.

A look at the realities of a North Korea nuclear threat
A solid-fuel "Pukguksong-2" missile lifts off during its launch test at an undisclosed location in North Korea. The North has achieved what many observers thought was beyond them, and ahead of schedule.

Dileep's bail plea pushed to Friday
The Kerala High Court has deferred the verdict on actor Dileep's bail plea to August 18. During the star night rehearsal, Dileep had stayed in Hotel Abad Plaza in Kochi .

ECP rejects Imran Khan's petition against contempt proceedings
Khan had filed the review application against the EC's order to produce the PTI's financial documents before the commission. The ECP had issued the contempt notice to Khan on January 24 over his "scandalous remarks" about the commission.

Dustin Pedroia heads back to the disabled list
After starting at DH for one game, Pedroia's knee issues cropped back up and he has not played since. Boston recalled Robby Scott from Triple-A Pawtucket in response to Pedroia's return to DL.

North Korea threatens strike on Guam
From there, they flew over the Korean Peninsula and joined by South Korean Air Force KF-16 fighter jets before returning to Guam. During the Cuban missile crisis, former president Kennedy made sure the US didn't box in Khrushchev in order to maintain peace.

Matic is a 'gross loss' for us, admits Chelsea boss Conte
So I don't think he'll be a huge loss to them. "I think he's very similar in a way to Michael Carrick ". Nemanja Matic made 112 defensive actions in the Premier League last season.

Danish submarine creator arrested over missing reporter
He has denied responsibility for the fate of 30-year-old Kim Wall, saying she had disembarked before his vessel went down. Madsen (46) financed his submarine project through crowdfunding and completed the submarine, the UC3 Nautilus, in 2008.

DOH warns public vs bird flu
PiƱol said Pampanga has been placed under a state calamity after the outbreak affected six poultry farms in San Luis town.